Systematic Financial Management LP Raises Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Systematic Financial Management LP increased its stake in InMode Ltd. (NASDAQ:INMD - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,026,823 shares of the healthcare company's stock after buying an additional 44,712 shares during the period. Systematic Financial Management LP owned 1.48% of InMode worth $17,148,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of InMode during the 4th quarter worth approximately $87,000. Farther Finance Advisors LLC boosted its position in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after purchasing an additional 1,154 shares in the last quarter. Covestor Ltd grew its stake in InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after purchasing an additional 723 shares during the period. Lazard Asset Management LLC raised its holdings in InMode by 6,128.7% in the fourth quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock worth $105,000 after purchasing an additional 6,190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in InMode in the fourth quarter worth $114,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Trading Up 1.6%

NASDAQ:INMD traded up $0.23 on Tuesday, reaching $14.76. 963,227 shares of the stock traded hands, compared to its average volume of 1,188,327. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of 6.28 and a beta of 2.02. InMode Ltd. has a 12 month low of $13.68 and a 12 month high of $19.85. The company's fifty day simple moving average is $15.92 and its 200 day simple moving average is $17.32.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The firm had revenue of $77.87 million for the quarter, compared to analysts' expectations of $82.21 million. During the same quarter in the previous year, the company earned $0.32 EPS. The company's quarterly revenue was down 3.0% compared to the same quarter last year. Equities analysts anticipate that InMode Ltd. will post 1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Barclays lowered their price objective on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Jefferies Financial Group dropped their price objective on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. Needham & Company LLC restated a "hold" rating on shares of InMode in a report on Monday, April 28th. Robert W. Baird downgraded shares of InMode from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Finally, UBS Group dropped their price target on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $18.54.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.